Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Gilteritinib Fumarate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 49,553Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Gilteritinib hemifumarate, Asp-2215 hemifumarate, 1254053-84-3, Gilteritinib fumarate [usan], Asp2215 hemifumarate, 5rzz0z1gjt
    Molecular Formula
    C62H92N16O10
    Molecular Weight
    1221.5  g/mol
    InChI Key
    UJOUWHLYTQFUCU-WXXKFALUSA-N
    FDA UNII
    5RZZ0Z1GJT
    Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (E)-but-2-enedioic acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
    2.1.2 InChI
    InChI=1S/2C29H44N8O3.C4H4O4/c2*1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36;5-3(6)1-2-4(7)8/h2*5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34);1-2H,(H,5,6)(H,7,8)/b;;2-1+
    2.1.3 InChI Key
    UJOUWHLYTQFUCU-WXXKFALUSA-N
    2.1.4 Canonical SMILES
    CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=CC(=O)O)C(=O)O
    2.1.5 Isomeric SMILES
    CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=C/C(=O)O)\C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    5RZZ0Z1GJT
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Gilteritinib Hemifumarate

    2. Asp-2215 Hemifumarate

    3. 1254053-84-3

    4. Gilteritinib Fumarate [usan]

    5. Asp2215 Hemifumarate

    6. 5rzz0z1gjt

    7. 1254053-84-3 (hemifumarate)

    8. 2-pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2h-pyran-4-yl)amino)-, (2e)-2-butenedioate (2:1)

    9. 2-pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2h-pyran-4-yl)amino]-, (2e)-2-butenedioate (2:1)

    10. 6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2h-pyran-4-yl)amino)pyrazine-2-carboxamide Hemifumarate

    11. Unii-5rzz0z1gjt

    12. Xospata (tn)

    13. (e)-but-2-enedioic Acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide

    14. Chembl3301603

    15. Schembl21819929

    16. Dtxsid001027950

    17. Gilteritinib Fumarate (jan/usan)

    18. Gilteritinib Fumarate [jan]

    19. Gilteritinib Fumarate [who-dd]

    20. Gilteritinib Fumarate [orange Book]

    21. D10800

    22. Q27262795

    2.4 Create Date
    2014-08-25
    3 Chemical and Physical Properties
    Molecular Weight 1221.5 g/mol
    Molecular Formula C62H92N16O10
    Hydrogen Bond Donor Count8
    Hydrogen Bond Acceptor Count24
    Rotatable Bond Count20
    Exact Mass1220.71823320 g/mol
    Monoisotopic Mass1220.71823320 g/mol
    Topological Polar Surface Area317 Ų
    Heavy Atom Count88
    Formal Charge0
    Complexity904
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Drug and Medication Information
    4.1 Drug Indication

    Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01EX13